Martinez Bueno A, Molina MA, Fielding A, et al. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO 2017, abstract LBA42.
BRAF-MEK-remming bij nieuw gediagnosticeerd papillair craniofaryngeoom
nov 2023 | Neuro-oncologie